Elsevier Inc.

SHERPA: Unknown

People

  1. Aghajanian
    Aghajanian
  2. Abu-Rustum
    Abu-Rustum
  3. Chi
    Chi
  4. O'Cearbhaill
    O'Cearbhaill
  5. Sabbatini
    Sabbatini
  6. Leitao
    Leitao
  7. Tew
    Tew
  8. Makker
    Makker
  9. Grisham
    Grisham
  10. Hensley
    Hensley

Groups

  1. Department of Medicine (59)
  2. GDMT, Medicine (59)
  3. Gynecologic Medicine Service (59)
  4. Gynecology Disease Management Team (59)
  5. Solid Tumor Oncology Division (59)
  6. Surgery (25)
  7. GDMT, Surgery (22)
  8. GDMT, Pathology and Laboratory Medicine (15)
  9. Hematologic Malignancies, Division of (12)
  10. Survivorship Research (10)
Search Within
  1. "Meeting abstract"
  2. "Carol Aghajanian"
Formats
  1. Meeting Abstract (59)
Groups
  1. Department of Medicine (59)
  2. GDMT, Medicine (59)
  3. Gynecologic Medicine Service (59)
  4. Gynecology Disease Management Team (59)
  5. Solid Tumor Oncology Division (59)
  6. Surgery (25)

More Groups

People
  1. Carol Aghajanian (59)
  2. Nadeem Abu-Rustum (15)
  3. Dennis Chi (13)
  4. Richard Barakat (12)
  5. Roisin O'Cearbhaill (12)
  6. Paul Sabbatini (10)

More People

Years
  1. 2023 (5)
  2. 2022 (8)
  3. 2021 (4)
  4. 2020 (14)
  5. 2019 (1)
  6. 2017 (1)

More Years

Publications
  1. Gynecologic Oncology (51)
  2. European Journal of Cancer (3)
  3. International Journal of Radiation Oncology, Biology, Physics (3)
  4. Seminars in Oncology (2)

Results (59)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of newly diagnosed stage II ovarian, primary peritoneal and fallopian tube cancer receiving intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab
    Meeting Abstract

    Washington, C. R.; Miller, A.; Moore, K. N.; Bell-McGuinn, K. M.; Schilder, R.; Walker, J. L.; Brady, W. E.; O'Cearbhaill, R. E.; Guntupalli, S. R.; Armstrong, D. K.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Anti-tumor activity of veliparib during combination phase with chemotherapy in velia study
    Meeting Abstract

    O'Malley, D. M.; Bookman, M. A.; Moore, K. N.; Fleming, G. F.; Brady, M. F.; Swisher, E. M.; Aghajanian, C.; Steffensen, K. D.; Friedlander, M.; Okamoto, A.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Exploring the relationship between homologous recombination score and progression-free survival in BRCA wildtype ovarian carcinoma: Analysis of veliparib plus carboplatin/paclitaxel in the velia study
    Meeting Abstract

    Swisher, E. M.; Kaufmann, S. H.; Birrer, M. J.; Levine, D. A.; Moore, K. N.; Fleming, G. F.; Coleman, R. L.; Bookman, M. A.; Timms, K. M.; Sullivan, D. M.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Mutation detection in cell-free DNA using ultra-high depth sequencing in prospectively collected newly diagnosed endometrial cancer patients
    Meeting Abstract

    Ashley, C. W.; Brown, D.; Lakhman, Y.; Nincevic, J.; Stylianou, A.; Wu, M.; Selenica, P.; Patel, J. A.; Berger, M. F.; Leitao, M. M. Jr; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Circulating cell-free DNA in patients with newly diagnosed and recurrent cervical cancer
    Meeting Abstract

    Kim, S. H.; Wu, M.; Stylianou, A.; Ghafoor, S.; Lakhman, Y.; Park, K. J.; Leitao, M. M. Jr; Sonoda, Y.; Gardner, G. J.; Broach, V.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial
    Meeting Abstract

    Swisher, E. M.; Coleman, R. L.; Bookman, M. A.; Brady, M. F.; Fleming, G. F.; Friedlander, M.; Cunningham, M. J.; Tewari, K. S.; Edraki, B.; Moxley, K.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent high-grade and low-grade serous ovarian cancer
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; McDonnell, A.; Iasonos, A.; Zhou, Q.; Li, K.; Girshman, J.; O'Cearbhaill, R. E.; Zamarin, D.; Aghajanian, C.
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study
    Meeting Abstract

    Bae-Jump, V. L.; Sill, M.; Gehrig, P. A.; Moxley, K.; Hagemann, A. R.; Waggoner, S. E.; O'Cearbhaill, R. E.; McDonald, M.; DiSilvestro, P. A.; Sperduto, P.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Tolerability and adverse events experienced by women with ovarian cancer treated with intravenous or intraperitoneal chemotherapy plus veliparib and bevacizumab based on BRCA status
    Meeting Abstract

    Gillen, J.; Miller, A.; Moore, K. N.; Bell-McGuinn, K. M.; Schilder, R.; Walker, J. L.; Brady, W. E.; O'Cearbhaill, R. E.; Guntupalli, S. R.; Armstrong, D. K.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Outcomes based on treatment regimen in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer receiving intravenous or intraperitoneal platinum-based chemotherapy in combination with veliparib and bevacizumab
    Meeting Abstract

    Washington, C. R.; Miller, A.; Moore, K. N.; Bell-McGuinn, K. M.; Schilder, R.; Walker, J. L.; Brady, W. E.; O'Cearbhaill, R. E.; Guntupalli, S. R.; Armstrong, D. K.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save